1. Introduction {#sec0005}
===============

Intracerebral hemorrhage (ICH) can be defined as any intracranial vault bleeding, including the brain parenchyma and surrounding meningeal spaces ([@bib0040]). IVH is a condition in which blood leaks into the intracranial vault leading to hematoma formation ([@bib0040]) that further damages the ventricles leading to cerebrospinal fluid leakage which cumulatively causes symptoms such as sudden tingling, weakness, numbness, paralysis, severe headache, difficulty swallowing or vision, loss of balance or vision coordination, difficulty understanding, speaking reading or writing and a change in level of consciousness and alertness marked by stupor, lethargy, sleepiness or coma. Bleeding directly into the ventricles from a source or lesion is in contact with or part of a ventricular wall as intraventricular hemorrhage (IVH) is known as a vascular malformation ([@bib0090]). The signs and symptoms include multiple cognitive, emotional and physical impairments, such as aphasia, gaze deviation hemianopia, hyperactive tendon jerks, muscle stiffness, thus interfering with regular movements, voice and gait impacting social quality of life, and the ability to work in brain hemorrhagic patients ([@bib0225]; [@bib0365]; [@bib0350]; [@bib0195]). (ICH is the least treatable form of stroke and associated with the worst prognosis in up to 40 % of cases, ICH further complicated by IVH which leads to condition hydrocephalus and increases case mortality up to 80 %. Depending on the underlying cause of bleeding ICH is classified as either primary or secondary Primary ICH, which accounts for 78--88% of cases, is caused by the spontaneous rupture of small vessels weakened by chronic hypertension or amyloid angiopathy ([@bib0010]). Secondary ICH occurs in combination with trauma, vascular abnormalities, tumors or coagulation impaired ([@bib0265]).

There are currently no specific FDA-approved post-brain hemorrhage therapy medications to enhance functional outcomes in ICH patients due to their various injury mechanisms ([@bib0095]). Primary ICH contributes to blood leakage in the brain parenchyma and further raises intracranial pressure that is responsible for killing neurons and glial cells ([@bib0370]). Various preclinical studies show that secondary brain injury following ICH is caused by cytotoxicity interactions ([@bib0125]), excitotoxicity, oxidative stress, inflammation, and mitochondrial dysfunction ([@bib0015]) from red blood cell lysis products and plasma component accumulation ([@bib0055]). However, it remains to be thoroughly elucidated the exact pathophysiological processes underlying ICH. (Elevation in intracranial pressure and acute vasoconstriction are two major factors responsible for reduced cerebral blood flow responsible for ischemic conditions. Initial hematoma induces glutamate release and then leads to oxidative stress and mitochondrial dysfunction). The most important implications for ICH pathogenesis are oxidative stress and neuronal cell damage associated with cognitive decline ([@bib0105]; [@bib0150]).

In the delayed phase of ICH, pathologically released noxious protease substances such as matrix metalloproteinase (MMP-9) from neutrophils, and activated microglia cause structural damage to the blood-brain barrier (BBB) leading to brain swelling ([@bib0340]). The release of erythrocyte lysis products such as iron which catalyzes the development of free radicals and reactive oxygen species (ROS) is the main mediator of the inflammatory cascade which leads to cell death and perihematomal swelling. Mitochondrial dysfunction contributes significantly to the deficiency of the results produced by adenosine triphosphate (ATP) in the failure of cellular ion pumps causing cytotoxic swelling and neuronal apoptosis ([@bib0315]) (Hence, neuroprotection in ICH needs a combined approach of decreasing different byproducts of secondary brain damage such as oxidative stress and mitochondrial dysfunction and restoring the antioxidant mechanism in the brain).

Specific ICH experimental animal models are used to research ICH pathophysiology and pharmacological interventions (including the micro balloon model ([@bib0295]), the bacterial collagenase injection model ([@bib0190]) and the autologous blood (ALB) injection model ([@bib0320]., [@bib0295]; [@bib0190]; [@bib0320]). We tried to use a low volume of autologous blood to minimize the mortality rate. Because the combined ICH and IVH model has high mortality due to the use of a large volume of autologous blood. For this, in the current study, we injected low volume (20 microliters) of autologous blood into the rat brain to ensure the presence of blood in both brain parenchyma and ventricles and low mortality rates (5.4 %) compared to other brain hemorrhagic studies ([@bib0320]; [@bib0195], Marinkovic and Strbian, 2014). Intracerebroventricular (ICV) administration of autologous blood (ALB) has been shown to induce marked neurological deficits and neuronal cell damage in experimental rats. In the combined ALB injection model, the hematoma size is controllable, which depends on the amount of blood injected. This blood model mimics a single large bleed that is thought to occur in most ICH patients and is most commonly used to investigate mechanisms of hemorrhagic damage in experimental rats.

In addition, combined autologous blood (ALB) injection into the brain of rats triggers hemorrhage as a disease that further interferes with the normal functioning of neuronal mitochondria such as CoQ10 insufficiency and ETC-complex dysregulation ([@bib0155]), which is also responsible for neuropathological cascades such as increases neuroinflammatory cytokines ([@bib0035]), oxidative stress ([@bib0075]), neurotransmitter imbalance, ([@bib0245]) failure of cellular pumps causing cytotoxic swelling and neuronal apoptosis. Nonetheless, in the prevention of post-brain hemorrhagic behavioral and neurochemical changes, there is no specific drug treatment available and only effective drug therapy is required to provide symptomatic relief like donepezil (DNP) ([@bib0200]), memantine (MEM) ([@bib0140]), celecoxib (CLB) ([@bib0240]), and pregabalin (PGB) ([@bib0270]).

To restore the neuronal integrity and prevent neurological deficits solanesol (SNL) as a coenzyme Q10 (CoQ10) precursor is used in the current study ([@bib0210]). Solanesol is a 45 carbon isoprenoid isolated from tobacco leaves ([@bib0330]) (*Nicotiana tobacum*), tomato (*Solanum lycopersicum*) ([@bib0005]), potato (*Solanum tuberosum*) ([@bib0050]), eggplant (*Solanum melongena*) and pepper (*Solanum melongena*) ([@bib0175]) (Tobacco has the highest SNL content among all the solanaceous plant). SNL is the starting medium for the synthesis of ethylenediamine (SDB) CoQ9, coenzyme Q10, vitamin-K2, vitamin-E and N-solanesyl-N, N′-bis-(3,4-dimethoxybenzyl) ([@bib0050]). It is commonly used as a crucial intermediate for the synthesis of ubiquinone drugs in the pharmaceutical industry (e.g., CoQ10) ([@bib0390]).

SNL is a precursor of CoQ10 and a powerful antioxidant with anti-inflammatory properties and membrane stability ([@bib0120]; [@bib0250]). Because, CoQ10 is an essential co-factor in the respiratory chain of the mitochondria and can restore the loss of mitochondrial transmembrane capacity, resulting in reduced mitochondrial ROS production and thus protecting the mitochondria and cellular components from oxidative damage.

CoQ10 (2, 3 dimethoxy-5-methyl-6-decaprenyl benzoquinone) is the most common coenzyme of 10 repeated isoprene units in human mitochondria, also known as ubiquinone ([@bib0345]; [@bib0020]). CoQ10 is a part of the electron transport chain that receives electrons from complex-I and pumps protons across the inner mitochondrial membrane and moves the electrons to complex-II, which is also responsible for ATP production ([@bib0235]; [@bib0065]) and will reduce oxidative neuron damage and enhance animal behavior. ([@bib0210]). CoQ10 has documented potential for treating Autism ([@bib0290]), migraine ([@bib0285]), Huntington\'s disease ([@bib0210]), and other neurodegenerative diseases such as Parkinson\'s disease, Amyotrophic lateral sclerosis, Alzheimer\'s disease, and multiple sclerosis ([@bib0205]; Shults et al., 2004). The present study, therefore, investigated the potential of solanesol alone and in combination with approachable therapy against the combined intracerebral and intraventricular hemorrhage model induced by autologous blood injection.

2. Material and methods {#sec0010}
=======================

2.1. Experimental animals {#sec0015}
-------------------------

Adult Wistar rats (250−300 g, total animal = 54, 30 male and 24 female) obtained free access to food and water from the Central Animal House facility of ISF College of Pharmacy, Moga, Punjab (India) (The total number of animals housed under a 12-h light/12-h dark cycle for at least 1 week before the start of the experiment in polyacrylic cages (three rats per cage) with free access to food and water). All behavioral parameters were tested from 9:00 am to 17:00 h. The study protocol approved by the Institutional Animal Ethics Committee (IAEC / CPCSEA / M 23/372) and experiments conducted under the guidelines of the Indian National Science Academy (INSA) for the use and care of experimental animals.

2.2. Drugs and chemicals {#sec0020}
------------------------

The test drugs Solanesol (SNL), Pregabalin (PGB), Celecoxib (CLB), Memantine (MEM), and Donepezil (DNP) were procured from BAPEX Pharmaceuticals, India as *ex-gratia* samples. Heparin sodium injection (1000 USP units per ml; Baxter Healthcare Corporation). Sterile alcohol preparation pads (Phoenix Healthcare Solutions), sterile saline solution (0.9 % (wt/vol) NaCl in distilled water). Neomycin (10 g; GSK), Gentamycin (80 mg; Intogen), Lignocaine gel (Lox 2% Jelly; Neon Laboratories Limited), Sodium pentobarbital (Sanofi Aventis, India). SNL dissolved in water with 2% ethanol administered by the oral route *(p.o.).* PGB 30 mg/kg ([@bib0310]), CLB 20 mg/kg ([@bib0305]), MEM 20 mg/kg ([@bib0180]), and DNP 3 mg/kg ([@bib0385]) dissolved in saline and administered by intraperitoneally *(i.p.*). All other chemicals used in the study are of analytical grade. Solutions of the drugs and chemicals freshly prepared before use.

2.3. Experimental protocol schedule {#sec0025}
-----------------------------------

The total duration of the study was 35 days ([@bib0100]). On day 0 autologous blood (ALB) was administered intracerebroventricularly. SNL chronically administered from day 1 after ALB administration until the end of the study (the 35th day) ([Fig. 1](#fig0005){ref-type="fig"}). Dose selection was done according to previous studies ([@bib0210]). Treatment with standard drugs such as CLB, MEM, PGB, and DNP also started from day one of the studies. Animals randomly assigned to 9 groups (n = 6 for each group). Group 1 Sham Control, Group 2 Solanesol *perse* (60 mg/kg, *p.o.*), Group 3- ALB (20 μl, *i.c.v.*), Group 4 ALB (20 μl, *i.c.v.*) + SNL (40 mg/kg, *p.o.*), Group 5 ALB (20 μl, *i.c.v.*) + SNL (60 mg/kg, *p.o*), Group 6 ALB (20 μl, *i.c.v.*) + SNL (60 mg/kg, *p.o*) + MEM (20 mg/kg, *i.p.*), Group 7 ALB (20 μl, *i.c.v.*) + SNL (60 mg/kg, *p.o*) + PGB (30 mg/kg, *i.p.*), Group 8 ALB (20 μl, *i.c.v.*) + SNL (60 mg/kg, *p.o*) + DNP (3 mg/kg, *i.p.*), Group 9 ALB (20 μl, *i.c.v.*) + SNL (60 mg/kg, *p.o*) + CLB (20 mg/kg, *i.p.*). Various behavioral assessments were carried out from day 1 to day 35. On day 36, the animals were deeply anesthetized with sodium pentobarbital (270 mg/mL, *i.p.*) and transcardially perfused with ice-cold PBS (0.1 M) followed by 4% paraformaldehyde in PBS for biochemical analysis of the brain. The experimental protocol summarized in ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Experimental protocol schedule (Behavioral and biochemical estimations).Fig. 1

2.4. Combined model of ICH-IVH in experimental animals {#sec0030}
------------------------------------------------------

Wistar rats were anesthetized using ketamine (75 mg/kg, i.p.) ([@bib0280]) and placed in a stereotactic frame. The head was shaved and a midline scalp incision was made to expose the skull, and a burr hole was made to introduce a calibrated hamilton syringe into the cerebroventricular part of the brain (stereotaxic coordinates from bregma: 0.26 mm antero-posterior, 2.2 mm medio-lateral, 5.0 mm dorso-ventral). The withdrawal site was disinfected with 70 % alcohol pads. Twenty five-G needle into the vein was inserted and a capillary tube was used to collect the blood. Twenty microlitres of ALB withdrawn from the central tail artery or lateral tail veins ([@bib0195]). Polyethylene tubing connected to the end of the hamilton syringe and filled with heparin where, 2 microlitres of air drawn into this tubing, followed by two microlitres of saline ([@bib0280]). This was done to leave a small air bubble between saline and heparin to prevent the mixing of these reagents. Again, 2 microlitres of air were drawn into the tubing followed by 20 microlitres of previously collected blood. Twenty microlitres of autologous blood were injected over 5 min ([@bib0375]). The burr hole filled with dental cement and fixative after completion of the infusion and the skin was sutured. \'Immediately post-surgery all rats received the subcutaneous injection of analgesic (ketoprofen, 1 mL/kg) and antibiotic gentamycin (35 mg/kg, i.p) was given twice a day of 12 h to prevent infection. Lignocaine and neomycin applied topically to prevent pain and infection, respectively. Animals were fed with oral glucose for 4 days along with a normal chow diet following surgery and then replaced with normal water and chow diet. Body weight was measured on days 1, 7, 14, 21, 28and 35 days of the experiment.

2.5. Parameters evaluated {#sec0035}
-------------------------

### 2.5.1. Behavioral parameters {#sec0040}

#### 2.5.1.1. Morris water maze {#sec0045}

The Morris water maze (MWM) was utilized to assess cognitive function by measuring escape latency on day 32, 33, 34, 35 and time spent in the target quadrant (TSTQ) recorded on day 35. The protocol was designed as described by [@bib0255]. (In the reference memory test, a platform was placed in the southwest quadrant 2 cm below water. Each animal was given 4 trials per day i.e. before day 0, starting from one of the release points in different directions. The inter-trial interval was 15 min). The working memory was executed on day thirty seconds after induction of hemorrhage, and escape latency was recorded. Each trial of the reference and working memory tests were ended when the rat stationed on the platform for 10 s or 120 s had elapsed. (The rats would be guided to stand on the platform if they did not find it within 120 s, and then the escape latency was recorded as 120 s.) On day 35, the rats were subjected to the probe trial, in which the platform was removed and TSTQ was recorded. All the data was recorded and analyzed by video tracking.

#### 2.5.1.2. Forced swim test {#sec0050}

On days 10, 20 and 30 post-ICH-IVH, each rat underwent the forced swim test (FST) based on an established protocol with minor modifications ([@bib0275]). Rats were placed individually in cylindrical tanks (height, 50 cm; diameter, 15 cm) containing 30 cm of water at 24 ± 1 °C. A camera recorded the movement of the rat for 5 min. (All the experimental rats underwent a pretest for 15 min to eliminate the acute stress of the water and to provide the animals with the ability to adapt to the water. Twenty-four hours after the pretest, the animals were tested for 5 min.). The immobility time was calculated by subtracting the total amount of mobility time over the 5 min of testing. The rat was judged to be immobile when it ceased struggling and remained floating motionless in an upright position in the water, making only small movements to keep its head above the water (Zhu et al., 2014).

#### 2.5.1.3. Beam crossing task {#sec0055}

The beam-walking test (1.0 cm diameter, 80 cm long beam) was performed to evaluate hind limb dysfunction on days 8, 16, 24 and 32 after surgery. The function of the right paralyzed hind limb was evaluated. Performance rated on a 7 point scale: (1) the rat was unable to place the affected hind limb on the horizontal surface of the beam; (2) the rat places the limb on the beam and maintains balance but unable to traverse the beam; (3) the rat traverses the beam dragging the affected hind limb; (4) the rat traverses the beam and places the affected hind limb on the horizontal surface of the beam once; (5) the rat crosses the beam and places the affected hind limb on the horizontal surface of the beam to aid during less than half of the steps; (6) the rat uses the affected hind limb to aid in more than half of the steps; and (7) the rat traverses the beam with only two-foot slips ([@bib0325]).

#### 2.5.1.4. Locomotor activity {#sec0060}

Locomotor activity was monitored on days 5, 15, 25 and 35 using an actophotometer (IMCORP, Ambala, India). (The motor activity in the actophotometer detected by photocells installed in the instrument). Animals were placed individually in the activity chamber for 3 min as a habituation period before making an actual recording. Each animal was observed over 5 min and expressed as counts per 5 min ([@bib0300]).

#### 2.5.1.5. Novel object recognition test {#sec0065}

On days 1, 11, 22 and 33post-ICH, an established protocol was used to test each rat in the novel object recognition test. (On the first day, the rat was placed in a cage and habituated to explore an open field for 5 min. On the second day, two identical novel objects (wooden brown cubes) were placed in the arena, and the rat was allowed to explore them for 10 min. After 1 h, the rat was given one novel object (white ball, 5 cm in diameter) and one familiar one (wooden brown cube) and allowed to explore for 5 min). A camera recorded the behaviors displayed by each rat during the test. We compared the total time spent exploring new and old objects. Time spent exploring an object included time in direct contact and time within the object area. The rat was considered in the object area if its nose was directed at the object and less than approximately two centimeters from it ([@bib0395]).

2.6. Mitochondrial ETC-complexes enzyme activity {#sec0070}
------------------------------------------------

### 2.6.1. Isolation of rat brain mitochondria {#sec0075}

Rat brain mitochondria were isolated using [@bib0025] method for mitochondrial enzyme complex activities. Isolated brains were homogenized, and homogenates then centrifuged at 13,000×*g* for 5 min at 4 °C. Pellets were re-suspended in isolation buffer with ethylene glycol tetra-acetic acid (EGTA) and spun again at 13,000×*g* at 4 °C for 5 min. The resulting supernatants were transferred to new tubes and topped off with isolation buffer with EGTA and again spun at 13,000×g at 4 °C for 10 min. Pellets containing pure mitochondria were resuspended in isolation buffer without EGTA. ([@bib0030])

### 2.6.2. Mitochondrial nicotinamide adenine dinucleotide dehydrogenase (NADH) (Complex-I) enzyme activity {#sec0080}

[@bib0165] method were used for the measurement of NADH dehydrogenase activity spectrophotometrically. (The method involves catalytic oxidation of NADH to NAD^+^ with subsequent reduction of cytochrome C. The reaction mixture contained 0.2 M glycylglycine buffer (pH 8.5), 6 mM NADH in 2 mM glycylglycine buffer, and 10.5 mM cytochrome C.) The reaction was initiated by the addition of a requisite amount of solubilized mitochondrial sample followed by an absorbance change at 550 nm for 2 min. The values expressed as nM/mg protein.

### 2.6.3. Succinate dehydrogenase (SDH) (complex-II) activity {#sec0085}

SDH measured spectrophotometrically using the method by [@bib0160]). The method involves the oxidation of succinate by an artificial electron acceptor, potassium ferricyanide. (The reaction mixture contained 0.2 M phosphate buffer (pH 7.8), 1% BSA, 0.6 M succinic acid, and 0.03 M potassium ferricyanide.) The reaction initiated by the addition of the mitochondrial sample followed by an absorbance change at 420 nm for 2 min. The values expressed as nM/mg protein.

### 2.6.4. Complex-V activity (ATPase) {#sec0090}

ATP synthase Enzyme Activity Microplate Assay Kit ab109714 was used to determine the activity of ATP synthase (Complex-V). (The ATP synthase enzyme was immunocaptured within the wells of the microplate and the enzyme activity measured by monitoring the decrease in absorbance at 340 nm). The conversion of ATP to ADP by ATP synthase is coupled to the oxidation reaction of NADH to NAD^+^ with a reduction in absorbance at 340 nm. The values expressed as nM/mg protein ([@bib0145]).

### 2.6.5. Mitochondrial ETC-complex CoQ~10~ level {#sec0095}

CoQ10 from brain tissues and mitochondria was extracted and measured by HPLC as described by [@bib0230]. Briefly, tissue or mitochondria were homogenized using a micro-glass tissue grinder in 0.5 mL potassium phosphate buffer pH 7.4 containing 1 mM dithiothreitol. The homogenate was treated with 2 mL of ethanol containing 1 μg/mL butylated hydroxytoluene (Sigma, St. Louis, MO) and ubiquinone was extracted with 5 mL hexane. After vigorous shaking, 4 mL of the hexane layer dried under N~2~. The residue dissolved in a hundred μl ethanol containing BHT and subjected to HPLC analysis. CoQ~9~ and CoQ~10~ quantified using the C~18~ column with a mobile phase methanol: hexane (90:10 v/v), detected at a wavelength of 275 nm. The values expressed as nM/mg protein.

### 2.6.6. Assessment of neurotransmitter level {#sec0100}

#### 2.6.6.1. Measurement of GABA and glutamate levels {#sec0105}

The GABA and glutamate levels were estimated by the method described by Donzanti ([@bib0070]) with slight modifications, which involved HPLC with an ECD. (A Waters standard system comprising a high-pressure isocratic pump, a 20 microlitres manual sample injector valve, a C~18~ reversed-phase column, and an ECD used in the study. The mobile phase comprised 100 mM anhydrous disodium hydrogen phosphate, 25 mM EDTA, and 22 % methanol (pH: 6.5). The electrochemical conditions for the experiment were +0.65 V, with sensitivity ranging from 5 to 50 nA. The separation was carried out at a flow rate of 1.2 mL/minutes, and the column temperature maintained at 40 °C. Samples (20 μl) injected manually through a rheodyne valve injector. On the day of the experiment, the frozen brain samples thawed and homogenized in 0.2 M perchloric acid. Then, the samples anteroposterior at 12,000×g for 15 min. The supernatant was derivatized using OPA/β-ME (o-pthalaldehyde/β-mercaptoethanol) and then filtered through the 0.22-mm nylon filters before being injected into the HPLC sample injector). Data were recorded and analyzed using Breeze software version 3.2 purchase from Waters HPLC. The amino acid concentrations calculated from the standard curve generated using a standard in the concentration range of 10--100 ng/ml. The values expressed as a percentage of the normal control group.

#### 2.6.6.2. Estimation of dopamine level {#sec0110}

The levels of dopamine in the brain were estimated via high-performance liquid chromatography (HPLC) using an electrochemical detector (ECD) ([@bib0135]). A Waters standard system comprising a high-pressure isocratic pump, a 20 microlitres manual sample injector valve, a C~18~ reversed-phase column, and an ECD used in the study. The mobile phase comprised of sodium citrate buffer (pH 4.5)--acetonitrile (87:13, v/v). The sodium citrate buffer comprised 10 mM citric acid, 25 mM NaH~2~HPO~4~, 25 mM EDTA (ethylene diamine tetra-acetic acid), and 2 mM 1-heptane sulfonic acid. The electrochemical conditions for the experiment were +0.75 V, with sensitivity ranging from 5 to 50 nA. The separation carried out at a flow rate of 0.8 mL/minutes. The samples (20 microlitres) were injected manually. On the day of the experiment, the frozen brain samples thawed and homogenized in a homogenizing solution containing 0.2 M perchloric acid. Then, the samples were centrifuged at 12,000×g for 5 min. The supernatant filtered through 0.22-mm nylon filters before being injected into the HPLC sample injector). Data were recorded and analyzed with Breeze software.

#### 2.6.6.3. Estimation of acetylcholine (Ach) {#sec0115}

A diagnostic kit (Krishgen diagnostics, India) was used to measure acetylcholine. Samples and all the reagents were prepared as described in the kit. The optical density of the reaction mixture was determined at 540 nm in the microtiter plate (Zeng et al. 2017).

### 2.6.7. Estimation of neuroinflammatory biomarkers {#sec0120}

#### 2.6.7.1. Estimation of TNF-α, IL-1β, IL-10 levels {#sec0125}

A diagnostic kit (Krishgen diagnostics, India) was used to measure TNF-α, IL-1β, IL-10. Samples and all the reagents were prepared as described in the kit. The optical density of the reaction mixture determined at 450 nm in the microtiter plate ([@bib0355]).

### 2.6.8. Protein estimation {#sec0130}

The protein content was measured using the coral protein estimation kit using the biuret method ([@bib0110]).

### 2.6.9. Assessment of oxidative stress markers {#sec0135}

#### 2.6.9.1. Preparation of rat brain homogenate {#sec0140}

On day 36, animals were sacrificed by decapitation; brains were removed and rinsed with ice-cold isotonic saline solution. Brain samples then homogenized with a chilled phosphate buffer 0.1 M phosphate buffer (7.4). The homogenate centrifuged at 10,500×g for 15 min, supernatant separated and aliquots used for biochemical estimation ([@bib0130]).

#### 2.6.9.2. Measurement of acetylcholinesterase (AChE) levels {#sec0145}

The quantitative measurement of acetylcholinesterase activity in the brain was performed according to the method described by Ellman ([@bib0085]). (The assay mixture contained 0.05 mL of supernatant, 3 mL of 0.01 M sodium phosphate buffer (pH 8), 0.10 mL of acetyl thiocholine iodide and 0.10 mL of DTNB (Ellman reagent).) The change in absorbance measured immediately at 412 nm spectrophotometrically. The enzymatic activity in the supernatant expressed as μmol/mg protein.

#### 2.6.9.3. Estimation of reduced glutathione levels {#sec0150}

Levels of glutathione in the brain were estimated according to the method described by Ellman ([@bib0080]). One ml supernatant precipitated with 1 mL of 4% sulfosalicylic acid and cold digested at 4 °C for 1 h. The samples centrifuged at 1200×g for 15 min. To 1 mL of the supernatant, 2.7 mL of phosphate buffer (0.1 M, pH 8) and 0.2 mL of 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) were added. The yellow color that developed was measured immediately at 412 nm using a spectrophotometer. The concentration of glutathione in the supernatant expressed as μM/mg protein ([@bib0300]).

#### 2.6.9.4. Assessment of malondialdehyde (MDA) levels {#sec0155}

The quantitative measurement of malondialdehyde (MDA) end product of lipid peroxidation--in brain homogenate was performed according to the method of [@bib0360]. The amount of MDA was measured, after its reaction with thiobarbituric acid, at 532 nm using a spectrophotometer (PERKIN ELMER UV/VIS Spectrophotometer, Lamda 20). The concentration of MDA expressed as nM/mg protein ([@bib0045]).

#### 2.6.9.5. Assessment of superoxide dismutase (SOD) activity {#sec0160}

The SOD activity assayed using the method described by [@bib0170]. The assay system comprises 0.1 mmol/L EDTA, 50 mmol/L sodium carbonate and 96 mmol/L of nitro blue tetrazolium. In the cuvette, 2 mL of the above mixture, 0.05 mL of hydroxylamine and 0.05 mL of the supernatant added and auto-oxidation of hydroxylamine measured for two minutes at 30′s interval by measuring the absorbance at 560 nm (PERKIN ELMER UV/VIS Spectrophotometer, Lamda 20). The activity of SOD expressed as units/mg protein ([@bib0045]).

#### 2.6.9.6. Estimation of nitrite levels {#sec0165}

The accumulation of nitrite in the supernatant, an indicator of the production of nitric oxide (NO), determined by a colorimetric assay using Greiss reagent (0.1 % N-(1-naphthyl) ethylenediamine dihydrochloride, 1% sulfanilamide and 2.5 % phosphoric acid) as described by [@bib0115]. Equal volumes of supernatant and Greiss reagent mixed, the mixture incubated for ten minutes at room temperature in the dark and the absorbance determined at 540 nm spectrophotometrically. The concentration of nitrite in the supernatant was determined from the sodium nitrite standard curve and expressed as μg/mL proteins ([@bib0300]).

#### 2.6.9.7. Gross pathological examination and measurement of hematoma size of rat brain {#sec0170}

Animals were sacrificed by decapitation on day 36; brains were removed for gross pathological analysis. Coronal sections were taken after observation of the whole rat brain. ([@bib0185]). For the measurement of hematoma size, the brain was removed quickly, submerged for 1 min in ice-cold saline, and placed on a tissue chopper to determine the volume of the hematoma. Sectioned 2-mm thick brain pieces (coronally from the anterior pole to the posterior poles of the cerebral cortex) were placed on glass slides. A digital camera (Fujix digital camera, Fujifilm, Japan) was used to view all the parts of the brain that span the whole striatum. This took less than 5 min to take digital images of all brain parts including a hematoma in each brain section. The collected digital images were processed for the preparation of figures and converted to TIFF files for image analysis. The hematoma region (mm) in each brain segment was measured on day 36th after completion of the procedure through MOTICAM-BA310 image plus 2.0 analysis software. The volume of the hematoma scale (mm^3^) was measured for each coronal brain segment by conversion of the hematoma region (mm) ([@bib0335]).

The hematoma size (mm^3^) in each brain section was determined from the red area in the striatum by image analysis on the 36th day, after induction of ICH. The size of the hematoma was calculated in each coronal 2-mm-thick brain section by calculating the hematoma area (lXbxh).

2.7. Statistical analysis {#sec0175}
-------------------------

Graph Pad Prism (Graph Pad Software, San Diego, CA, USA) used for all statistical analyses. Values expressed as mean ± SEM. The behavioral assessment data analyzed by two-way analysis of variance (ANOVA) with drug-treated groups as between sessions and as within-subjects factors. The biochemical estimations analyzed by one-way ANOVA. Post hoc comparisons between groups were made using Tukey's post hoc test. p \< 0.001 was considered significant.

3. Results {#sec0180}
==========

3.1. Neuroprotective effect of SNL on body weight in ALB induced brain hemorrhagic rats {#sec0185}
---------------------------------------------------------------------------------------

Treatment with ALB induced a significant reduction in body weight compared to normal rats. Treatment with SNL 60 mg/kg perse showed no change in body weight over normal rats. Post-treatment with continuous administration of SNL 40 mg/kg and SNL 60 mg/kg successfully reversed the loss of body weight caused by ALB as compared to normal and 60 mg/kg perse. Treatment with SNL 60 mg / kg in combination with PGB 30 mg / kg has substantially and dose-dependently restored body weight relative to other standard drug treatment groups CLB 20 mg / kg, DNP 3 mg / kg, and MEM 20 mg / kg in the combined ICH-IVH rat model (p \< 0.001) ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2Effect of SNL on body weight in ALB induced ICH-IVH in rats.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus CLB20, DNP3, MEM20 (Two way ANOVA followed by Bonferroni's test)Fig. 2

3.2. Behavioral parameters {#sec0190}
--------------------------

### 3.2.1. Neuroprotective effect of SNL on spatial navigation task in ALB induced brain hemorrhagic rats using morris water maze {#sec0195}

During the reference memory test, the escape latency of the trained rats in the Morris water maze test gradually reduced. ALB induced ICH-IVH in rats increased the escape latency time on day 32, 33, 34, and 35 when compared to the normal group (p \< 0.001). Treatment with SNL 60 mg/kg perse did not show any difference in escape latency compared to normal rats. After hemorrhage, chronic treatment with SNL 40 mg/kg, and SNL 60 mg/kg decrease the latency time. Treatment with SNL 60 combined with DNP 3 substantially and dose-dependently increased the escape latency compared to SNL 60 in combination with MEM 20 mg/kg, PGB 30 mg/kg and CLB 20 mg/kg (p \< 0.001). On day 35, TSTQ was decreased in ALB mediated ICH-IVH rats compared to normal and SNL 60 mg/kg perse treated rats. Post-treatment with SNL 40 mg / kg and SNL 60 mg / kg considerably improved the TSTQ. Treatment with SNL 60 mg / kg combined with DNP 3 mg / kg significantly improved the duration of the escape latency compared to SNL 60 in combination with MEM 20 mg / kg, PGB 30 mg / kg and CLB 20 mg/kg (p \< 0.001) ([Fig. 3](#fig0015){ref-type="fig"}, [Fig. 4](#fig0020){ref-type="fig"}).Fig. 3Neuroprotective effect of SNL on escape latency in ALB induced ICH-IVH in rats using morris water maze.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus MEM20, PGB30 and CLB20 (Two way ANOVA followed by Bonferroni's test)Fig. 3Fig. 4Neuroprotective effect of SNL on time spent in target quadrant in ALB induced.ICH-IVH in rats using morris water maze.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus MEM20, PGB30 and CLB20 (Two way ANOVA followed by Bonferroni's test)Fig. 4

### 3.2.2. Neuroprotective effect of SNL on immobility using forced swim test in ALB induced brain hemorrhagic rats {#sec0200}

ALB induced ICH-IVH in rats, showing the depression-like activity increased immobility time in FST. Groups with only autologous blood, compared to normal rats, showed a significant increase in immobility time. Chronic SNL 60 mg/kg perse treatment showed no depression-like activity as compared to normal rats. Consequently, post-treatment with SNL 40 mg / kg and SNL 60 mg / kg for 35 days decreased the immobility time compared to normal and SNL 60 mg / kg *per se*. SNL 60 treatment in combination with PGB 30 mg / kg prodigiously improved immobility compared to SNL 60 mg / kg in combination with CLB 20 mg / kg, MEM 20 mg / kg and DNP 3 mg / kg (p \< 0.001) ([Fig. 5](#fig0025){ref-type="fig"}).Fig. 5Neuroprotective effect of SNL on immobility using forced swim test in ALB.induced ICH-IVH in rats.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus CLB20, MEM20, and DNP3 (Two way ANOVA followed by Bonferroni's test)Fig. 5

### 3.2.3. Neuroprotective effect of SNL on the neurological score using beam crossing task in ALB induced brain hemorrhagic rats {#sec0205}

During beam crossing activity, ICH-IVH rats induced ALB exhibited greater dysfunction of the hind limbs compared with normal rats. Compared to normal animals, single autologous blood groups showed a significant decrease in neurological scores SNL 60 mg/kg perse treatment showed no motor dysfunction when compared with normal rats. Post-treatment with SNL 40 mg / kg and SNL 60 mg / kg over 35 days considerably improved the neurological performance. Treatment with SNL 60 mg / kg in combination with CLB 20 mg / kg significantly and dose-dependently improved the neurological score compared to SNL 60 mg / kg in combination with PGB 30 mg / kg, MEM 20 mg / kg, and DNP 3 mg / kg (p \< 0.001) ([Fig. 6](#fig0030){ref-type="fig"}).Fig. 6Neuroprotective effect of SNL on neurological score using beam crossing task in.ALB induced ICH-IVH in rats.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus CLB20, MEM20, and DNP3 (Two way ANOVA followed by Bonferroni's test)Fig. 6

### 3.2.4. Neuroprotective effect of SNL on locomotor activity using actophotometer in ALB induced brain hemorrhagic rats {#sec0210}

In rats, ALB induced ICH-IVH caused a significant decline in locomotive activity as compared to normal rats. Chronic SNL 60 mg/kg perse treatment showed no improvement in locomotive behavior as compared with normal rats. Post-treatment with SNL 40 mg/kg and SNL 60 mg/kg during 35 days improved the locomotive activity significantly. Treatment with SNL 60 mg / kg in combination with PGB 30 mg / kg significantly improved the locomotion compared with SNL 60 mg / kg in combination with CLB 20 mg / kg, MEM 20 mg / kg and DNP 3 mg / kg (p \< 0.001) ([Fig. 7](#fig0035){ref-type="fig"}).Fig. 7Neuroprotective effect of SNL on locomotor activity using actophotometer in ALB.induced ICH-IVH in rats.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus CLB20, MEM20 and DNP3 (Two way ANOVA followed by Bonferroni's test)Fig. 7

### 3.2.5. Neuroprotective effect of SNL on exploration time using novel object recognition task in ALB induced brain hemorrhagic rats {#sec0215}

In the novel object recognition test, ALB induced ICH-IVH in rats with impaired memory as compared to normal rats and confirmed damage to hippocampal memory formation. Groups with only autologous blood, compared with normal rats, showed a significant reduction in exploration times. Chronic SNL 60 mg/kg perse treatment showed no memory alteration as compared to normal rats. Posttreatment with SNL 40 mg/kg and SNL 60 mg/kg significantly improved the time of exploration. Treatment with SNL 60 mg / kg in combination with MEM 20 mg / kg increased the exploration time significantly and dose-dependently compared to SNL 60 mg / kg in combination with DNP 3 mg / kg, CLB 20 mg / kg and PGB 30 mg / kg (p \< 0.001) ([Fig. 8](#fig0040){ref-type="fig"}).Fig. 8Neuroprotective effect of SNL on exploration time using novel object recognition task in ALB induced ICH-IVH in rats.Data expressed as mean ± SEM (n = 6). \* p \< 0.001 versus sham control and SNL60 *perse*; \# p \< 0.001 versus ALB; \#@ p \< 0.001 versus ALB + SNL40; \$ p \< 0.001 versus ALB + SNL60; \$β p \< 0.001 versus DNP3 CLB20, and PGB30 (Two way ANOVA followed by Bonferroni's test)Fig. 8

3.3. Neuroprotective effect of SNL on mitochondrial enzyme complexes (Complex I, II and V) and CoQ~10~ in ALB induced brain hemorrhagic rats {#sec0220}
--------------------------------------------------------------------------------------------------------------------------------------------

ALB mediated ICH-IVH compared to normal and SNL 60 mg/kg perse rats in rats with damaged mitochondrial enzyme complex (I, II, and IV) activities and levels of CoQ10. Nonetheless, as opposed to the ALB group 35 days of treatment with SNL 40 mg/kg and SNL 60 mg/kg substantially restored mitochondrial enzyme complex activity (I, II, and V) and CoQ10 levels. In addition, the combination of SNL 60 mg / kg with PGB 30 mg / kg significantly restored enzyme-complex enzyme activity (I, II and IV) and CoQ10 levels compared to SNL 60 mg / kg given in combination with DNP 3 mg / kg, MEM 20 mg / kg, and CLB 20 mg / kg (p \< 0.001) ([Table 1](#tbl0005){ref-type="table"}).Table 1Neuroprotective effect of SNL on mitochondrial enzyme complexes (Complex I, II and V) and CoQ~10~ in ALB induced ICH-IVH in rats.Table 1GroupsComplex- I (nM/mg protein)Complex-II (nM/mg protein)Complex-V (nM/mg protein)CoQ~10~ (nM/g protein)**Sham Control**14.0 ± 0.259.03 ± 0.24735.0 ± 7.7557.28 ± 0.06**SNL60 *perse***14.1 ± 0.309.06 ± 0.19735.0 ± 6.7037.38 ± 0.15**ALB**2.83 ± 0.30\*1.20 ± 0.20\*226.8 ± 4.564\*0.83 ± 0.09\***ALB + SNL40**4.50 ± 0.42^\#^2.23 ± 0.19^\#^329.0 ± 16.48^\#^1.91 ± 0.23^\#^**ALB + SNL60**6.00 ± 0.25^\#@^3.23 ± 0.17^\#@^376.7 ± 6.652^\#@^2.63 ± 0.15^\#@^**ALB + SNL60+ CLB20**7.50 ± 0.42^\$^4.48 ± 0.09^\$^449.5 ± 9.986^\$^3.70 ± 0.21^\$^**ALB + SNL60+ MEM20**8.95 ± 0.09^\$^5.38 ± 0.17^\$^528.7 ± 5.993^\$^4.68 ± 0.08^\$^**ALB + SNL60+ DNP3**10.6 ± 0.33^\$^6.36 ± 0.15^\$^576.2 ± 7.981^\$^5.55 ± 0.13^\$^**ALB + SNL60+ PGB30**12.3 ± 0.21^\$β^7.80 ± 0.22^\$β^636.2 ± 17.36^\$β^6.33 ± 0.08^\$β^[^1]

3.4. Neuroprotective effect of SNL on neurotransmitter levelsin ALB induced brain hemorrhagic rats {#sec0225}
--------------------------------------------------------------------------------------------------

In contrast to the sham control group (p \< 0.001), the group treated with ALB alone showed a low level of GABA and dopamine and a high level of glutamate. Significantly and dose-dependently, post-treatment with SNL 40 mg/kg and SNL 60 mg/kg for 35 days prevented increases in GABA, dopamine and glutamate levels (p \< 0.001). The combination of SNL 60 mg/kg with MEM 20 mg/kg significantly improved dopamine levels and reduced the elevated levels of glutamate compared to SNL 60 mg/kg in combination with DNP 3, PGB 30 and CLB 20 (p \< 0.001). The combination of SNL 60 mg / kg with PGB 30 mg / kg also lowered GABA levels in comparison with SNL 60 mg / kg in combination with MEM 20, DNP 3 and CLB 20 (p \< 0.001) ([Table 2](#tbl0010){ref-type="table"}).Table 2Neuroprotective effect of SNL on neurotransmitter levels in ALB induced ICH-IVH in rats.Table 2GroupsDopamine[a](#tblfn0005){ref-type="table-fn"}Glutamate[a](#tblfn0005){ref-type="table-fn"}GroupsGABA[b](#tblfn0010){ref-type="table-fn"}(ng/mg tissue)(ng/mg tissue)(ng/mg tissue)**Sham Control**119.5 ± 8.09784.67 ± 2.16**Sham Control**118.7 ± 7.508**SNL60 *Perse***117.3 ± 6.15985 ± 0.89**SNL60 *Perse***116.7 ± 7.508**AB**11.97 ± 1.347\*153.7 ± 3.77**AB**4.633 ± 1.793\***AB + SNL40**27.95 ± 7.844^\#^129.2 ± 1.16**AB + SNL40**16.3 ± 4.260^\#^**AB + SNL60**44.7 ± 9.996^\#@^124 ± 2.098**AB + SNL60**29.13 ± 4.507^\#@^**AB + SNL60 + CLB20**60.13 ± 10.40^\$^119.2 ± 2.04**AB + SNL60 + CLB20**39.13 ± 4.507^\$^**AB + SNL60 + PGB30**75.92 ± 7.895^\$^111.8 ± 3.97**AB + SNL60 + DNP3**51.63 ± 4.096^\$^**AB + SNL60 + DNP3**91.67 ± 5.837^\$^104.3 ± 1.862**AB + SNL60 + MEM20**64.13 ± 6.400^\$^**AB + SNL60 + MEM20**107.7 ± 10.44^\$β^92 ± 0.8944**AB + SNL60 + PGB30**75.8 ± 6.047^\$β^[^2][^3]

3.5. Neuroprotective effect of SNL on acetylcholine and acetylcholinesterase levelsin ALB induced ICH-IVH in rats {#sec0230}
-----------------------------------------------------------------------------------------------------------------

The group treated with ALB alone showed a significantly low level of Ach and a high level of AchE when compared to the sham control group (p \< 0.001). Post-treatment with SNL 40 mg / kg and SNL 60 mg / kg has substantially and dose-dependently prevented improvements in Ach and AchE (p \< 0.001) levels for 35 days. In addition, the combination of SNL 60 mg / kg with DNP 3 mg / kg significantly improved Ach and decreased the elevated levels of AchE in contrast to SNL 60 given in combination with MEM 20 mg / kg, CLB 20 mg / kg and PGB 30 mg / kg (p \< 0.001) ([Table 3](#tbl0015){ref-type="table"}).Table 3Neuroprotective effect of SNL on acetylcholine and acetylcholinesterase levels in ALB induced ICH-IVH in rats.Table 3GroupsAchEAch(μmol/mg protein)(μmol/mg protein)**Sham Control**4.33 ± 3.678.71 ± 0.56**SNL60 *Perse***4.33 ± 3.678.63 ± 0.95**ALB**94.5 ± 6.41\*0.21 ± 0.11\***ALB + SNL40**79.67 ± 8.86^\#^1.45 ± 0.45^\#^**ALB + SNL60**65.0 ± 8.87^\#@^2.71 ± 0.18^\#@^**ALB + SNL60 + PGB30**51.17 ± 6.49^\$^3.96 ± 0.56^\$^**ALB + SNL60 + CLB20**37.2 ± 10.08^\$^5.38 ± 0.79^\$^**ALB + SNL60 + MEM20**23.1 ± 5.29^\$^6.63 ± 0.72^\$^**ALB + SNL60 + DNP3**9.23 ± 2.280^\$β^8 ± 0.70^\$β^[^4]

3.6. Neuroprotective effect of SNL on TNF-α, IL-6 and IL-1β levelsin ALB induced ICH IVH in rats {#sec0235}
------------------------------------------------------------------------------------------------

Intracerebroventricular administration of ALB significantly increased the level of pro-inflammatory markers i.e. TNF-α, IL-6 and IL-1β levels in the brain as compared to normal and SNL 60 mg/kg *perse* group. However, 35 days of treatment with SNL 40 mg/kg and SNL 60 mg/kg significantly and dose-dependently reduced the levels of TNF-α, IL-6, and IL-1β as compared to the ALB group. Further, combination of SNL 60 mg/kg with CLB 20 mg/kg significantly attenuated levels of TNF-α, IL-6 and IL-1β compared to SNL 60 given in combination with PGB 30 mg/kg, MEM 20 mg/kg and DNP 3 mg/kg (p \< 0.001) ([Table 4](#tbl0020){ref-type="table"}).Table 4Effect of SNL on TNF-α, IL-6 and IL-1β levels in ALB induced ICH-IVH in rats.Table 4GroupsNeuroinflammatory MarkersTNFα pg/mg proteinIL-1β pg/mg proteinIL-10 pg/mg protein**Sham Control**100.0 ± 2.8873.17 ± 2.5258.83 ± 0.54**SNL60 *perse***99.83 ± 2.8375.67 ± 2.2158.50 ± 0.56**ALB**300.8 ± 3.27\*577.5 ± 6.72\*24.17 ± 1.16\***ALB + SNL40**263.3 ± 5.11^\#^478.3 ± 7.50^\#^33.17 ± 0.83^\#^**ALB + SNL60**244.3 ± 3.11^\#@^430.8 ± 7.89^\#@^38.50 ± 0.56^\#@^**ALB + SNL60+DNP3**226.3 ± 3.26^\$^363.7 ± 4.21^\$^42.50 ± 0.42^\$^**ALB + SNL60+MEM20**204.0 ± 3.05^\$^315 ± 2.955^\$^48.33 ± 0.49^\$^**ALB + SNL60+PGB30**180.8 ± 3.00^\$^244.7 ± 7.90^\$^52.00 ± 0.57^\$^**ALB + SNL60+CLB20**160.0 ± 3.92^\$β^190.2 ± 5.57^\$β^55.17 ± 0.47^\$β^[^5]

3.7. Neuroprotective effect of SNL on brain oxidative stress (SOD, nitrite, concentration, GSH, and MDA) in ALB induced ICH-IVH in rats {#sec0240}
---------------------------------------------------------------------------------------------------------------------------------------

The sham control group showed no significant impact on SOD enzymes, the concentration of nitrite, GSH, and lipid peroxidation relative to SNL 60 mg/kg pers. However, the administration of ALB significantly increased levels of MDA, nitrite concentration, and depleted GSH and SOD enzymes as compared to the sham control group. 35 days of treatment with SNL 40 mg/kg and SNL 60 mg/kg significantly attenuated oxidative stress (decreased lipid peroxidation, nitrite concentration, and restored enzyme levels of GSH and SOD) compared to those in which only autologous blood was used. In comparison, the combination of SNL 60 mg / kg with PGB 30 mg / kg substantially reduced oxidative stress relative to SNL 60 in combination with DNP 3 mg / kg, MEM 20 mg / kg and CLB 20 mg / kg (p \< 0.001) ([Table 5](#tbl0025){ref-type="table"}).Table 5Neuroprotective effect of SNL on brain oxidative stress (SOD, nitrite concentration, GSH and lipid peroxidation (MDA)) in ALB induced ICH-IVH in rats.Table 5GroupsSODNitriteGSHMDA(U/mg)(μg/mL)(μmol/mg protein)(nM/mg protein)**Sham Control**45 ± 1.414301.5 ± 29.490.95 ± 0.0240.5833 ± 0.487**SNL60 *perse***43.67 ± 0.8165309.7 ± 20.340.96 ± 0.0270.7167 ± 0.479**ALB**12.67 ± 2.160\*818.3 ± 35.60\*0.01 ± 0.005\*13.03 ± 1.193\***ALB + SNL40**17.67 ± 2.582^\#^740.8 ± 21.28^\#^0.16 ± 0.033^\#^11.23 ± 1.120^\#^**ALB + SNL60**22.67 ± 2.658^\#@^671.2 ± 58.72^\#@^0.31 ± 0.059^\#@^9.35 ± 0.7176^\#@^**ALB + SNL60 + CLB20**27.67 ± 3.141^\$^584.2 ± 21.56^\$^0.45 ± 0.126^\$^7.583 ± 0.9453^\$^**ALB + SNL60 + MEM20**32.83 ± 2.787^\$^517.3 ± 21.58^\$^0.61 ± 0.069^\$^5.833 ± 1.181^\$^**ALB + SNL60 + DNP3**37.83 ± 1.472^\$^442 ± 20.91^\$^0.75 ± 0.099^\$^4.033 ± 1.041^\$^**ALB + SNL60 + PGB30**42.67 ± 4.227^\$β^373.2 ± 16.46^\$β^0.91 ± 0.040^\$β^2.033 ± 0.4590^\$β^[^6]

3.8. Neuroprotective effect of SNL on gross pathological changes and hematoma size in ALB induced brain hemorrhagic rats {#sec0245}
------------------------------------------------------------------------------------------------------------------------

AWhole-brain observation

The autologous blood induced whole rat brain showed damaged clotted outer layer followed by breach meninges compared to sham and perse rats treated with SNL 60 mg/kg. In the sham control and SNL60 mg/kg *perse* grouped rats\' brains showed optimally sized with clearly observable meninges. Furthermore, when compared with DNP 3 mg / kg, MEM 20 mg / kg and CLB 20 mg / kg treated rats, SNL 60 mg / kg in combination with PGB 30 mg / kg significantly improves morphological changes ([Fig. 9](#fig0045){ref-type="fig"}).BBrain section observationFig. 9Neuroprotective effect of SNL on gross pathological changes (whole rat brain) in ALB induced brain hemorrhagic rats.(a) Sham control i. Cerebral cortex ii. Hippocampus iii. Basal ganglia (b) SNL *perse* (c) ALB (d) ALB + SNL 40 (e) ALB + SNL 60 (f) ALB + SNL 60 + CLB 2 (g) ALB + SNL 60 + MEM 20 (h) ALB + SNL 60 + DNP 3 (i) ALB + SNL 60 + PGB 30 (Scale bar =2 mm)Note: Yellow circles are pointing to the site of the brain injuryFig. 9

During coronal sectioning, clearly observable brain tissue was observed in sham and SNL 60 mg/kg, perse treated rats. The coronal sections of ALB treated brains displayed cortical contusions, swellings, and severe subarachnoid hemorrhages associated with marked brain size reduction when compared to sham and perse-treated rats with SNL. In addition, compared to DNP 3 mg/kg, MEM 20 mg/kg and CLB 20 mg/kg treated rats, the combination of SNL 60 mg/kg with PGB 30 mg/kg substantially reduces autologous blood-mediated gross pathological changes ([Fig. 10](#fig0050){ref-type="fig"}).CHematoma sizeFig. 10Neuroprotective effect of SNL on gross pathological changes (brain section) in ALB induced brain hemorrhagic rats.(a) Sham control (b) SNL *perse* (c) ALB (d) ALB + SNL 40 (e) ALB + SNL 60 (f) ALB + SNL 60 + CLB 2 (g) ALB + SNL 60 + MEM 20 (h) ALB + SNL 60 + DNP 3 (i) ALB + SNL 60 + PGB 30 (Scale bar = 5 mm).Note: Yellow circles are pointing to the hematoma sizeFig. 10

The sham control group showed no significant effect on the size of the hematoma compared with SNL 60 mg/kg, perse. However, the administration of intracerebroventricular ALB significantly increased the size of hematoma compared to the sham control group and SNL 60 mg/kg perse. Treatment with SNL 40 mg/kg and SNL 60 mg/kg significantly reduced the size of the hematoma compared to those groups where only autologous blood was used. In addition, the combination of SNL 60 mg/kg with PGB 30 mg/kg substantially reduced hematoma size compared to SNL 60 in combination with DNP 3 mg/kg, MEM 20 mg/kg and CLB 20 mg/kg (p \< 0.001) ([Fig. 11](#fig0055){ref-type="fig"}).Fig. 11Neuroprotective effect of SNL on hematoma size in ALB induced brain hemorrhagic rats.Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus DNP3, MEM20 and CLB2 (One way ANOVA followed by Bonferroni's test)Fig. 11

4. Discussion {#sec0250}
=============

The present study shows SNL\'s neuroprotective potential against ALB-induced combined ICH-IVH model in rats. Besides, chronic treatment with SNL 60 mg/kg alone and in combination with standard drug therapy such as MEM 20 mg/kg, DNP 3 mg/kg, PGB 30 mg/kg, and CLB 20 mg/kg demonstrated the neuroprotective effect in improving various ICH-IVH-related pathological hallmarks. In recent decades, the outcome of ICH, the most severe form of stroke, has not improved (Van Asch et al., 2010), and treatment options are still mainly limited to supportive therapy. Surgical treatment options were mostly unsuccessful, particularly in cases where hemorrhage breaks into the ventricular system. A combined ICH-IVH model is a novel approach that effectively and reliably mimics intraventricular-associated parenchymal bleeding induced through a single autologous blood injection. This combined ICH-IVH model was validated and characterized using biochemical analysis. The model also produced emotional, behavioral, and cognitive deficits, closely mimicking the effects of human hemorrhage in those brain regions.

In our findings, twenty microliters of ALB were injected into rat brain for the induction of ICH-IVH. Our protocol duration was 35 days, however, and autologous blood volume was very low, with 20 microliters of ALB causing sufficient blood clotting leading to low mortality rates (5.4 %), hematoma formation and ventricular enlargement compared to other studies where high mortality was observed with increasing blood volume. In the pathophysiology of a brain hemorrhage, mitochondrial dysfunction, oxidative stress, and neuroinflammation have been well reported (Ostrowski et al., 2007). Hematoma development resulted in cognitive impairment, increased oxidative stress (as shown by elevated lipid peroxidation-MDA, nitric concentration and decreased glutathione depletion, SOD), impaired mitochondrial enzyme-complex activities (I, II and V) with reduced levels of CoQ10 and increased neuroinflammation (TNF-α, IL-1β, IL-10) in the hemorrhagic brain.

Despite having neuroprotective, anti-inflammatory, and anti-oxidant effects, SNL\'s exact action mechanism has not yet been properly understood ([@bib0380]). In the current study, 35-day SNL treatment significantly improves behavioral and motor impairment, oxidative damage, neuroinflammation and restored mitochondrial enzyme complex activity (I, II and V) in hemorrhagic rats, indicating its multiple target activities at various cellular and molecular cascades of complex ICH-IVH pathogenesis responsible for its neuroprotective effectiveness

CLB 20 demonstrated well in ischemia models for its anti-inflammatory, anti-apoptotic, and neuroprotective effects ([@bib0060]). Cerebral hemorrhage associated with caspase activation and the release of prostaglandin responsible for cell death and inflammation of the neurons ([@bib0305]). Therefore, prolonged treatment with CLB 20 in conjunction with SNL 60 decreased the elevated neuroinflammatory markers such as TNF-α, IL-1β, IL-10 for 35 days and also increased the neurological score in the beam crossing test relative to other therapies and disease classes, indicating its possible neuroprotective effects in the prevention of inflammation and neuronal mortality in patients.

The early period of ICH-IVH includes the accumulation of glutamate in the perihematomal region\'s extracellular space, which results in NMDA overstimulation causing excessive calcium inflow and subsequent excitotoxic injury ([@bib0260]). MEM 20, a non-competitive NMDA receptor antagonist, reported reducing excitotoxicity-induced injury and inhibiting hematoma expansion in combination with a decrease of the metalloproteinase-9 matrix (MMP-9) ([@bib0180]). In this study MEM 20 significantly improved recognition in NOR when used in combination with SNL 60 showing functional recovery with a decrease in glutamate levels and an increase in dopamine levels, providing new insight into the treatment of ICH-IVH with NMDAR blockers.

Donepezil, a specifically central acetylcholinesterase inhibitor, reported potentiating learning in stroke subjects by amplifying cholinergic feedback from Meynert\'s nucleus basalis into the cerebral cortex ([@bib0220]). Hematoma formation can cause contusion of these structures, resulting in reduced Ach synthesis and transportation to different parts of the brain, thereby affecting learning and memory ([@bib0385]; [@bib0215]). The present investigation reveals that when given in combination with SNL 60, DNP 3 increases the escape latency and reduces the time spent in a spatial navigation task in MWM in the target quadrant. It also reduced the elevated levels of AChE and raised the levels of Ach leading to cognitive changes by increasing the cholinergic system in the basal forebrain.

The neuroprotective effect of PGB 30 with epilepsy, anxiety and neuropathic pain is well reported ([@bib0240]). Besides being a structural analog of GABA, it has no direct action on GABA pathways. It is a novel ligand of alpha-2-delta (α2-*δ*) subunits of voltage-gated calcium channels (VGCC) using an animal model to exercise anticonvulsant, analgesic, and anxiolytic action. In the current study PGB 30 improved body weight, locomotion, and mobility time in FST in combination with SNL. It also preserved the complex functions of the mitochondrial, decreased oxidative stress, increased GABA levels relative to other standard drugs in conjunction with SNL. Confirming PGB 30 beneficial effects present in specific pathological ICH-IVH pathways. These results suggest that ALB mediated ICH-IVH causes complex mitochondrial dysfunction and increased oxidative stress, inflammatory cytokines, and altered neurotransmitter levels in rat brain, where chronic SNL administration, as a precursor to CoQ10, strengthened these neuropathological defects. In addition, chronic treatment with SNL alone and in conjunction with standard drugs (DNP 3, MM 20, CLB 20, PGB 30) significantly reduces oxidative stress, inflammatory cytokines and restores the amount of neurotransmitters in the brain of rats and restores mitochondrial functioning by improving the production of CoQ10 and ATP providing a better functional recovery. In our research, morphological and gross pathological changes followed by neurological functions and expressions of different biomarkers were examined after induction of hemorrhage in the rat brain which shows the neuroprotective effect of SNL, indicating the satisfactory repeatability and controllability of this novel animal model.

There are limitations to the current study. We perform a critical technique of a combined ICH-IVH model and there is no experimental animal model near the exact clinical conditions that can be 100 percent. Furthermore, the incapability of high-resolution MRI in this study made it difficult to distinguish between ICH and IVH.

5. Conclusion {#sec0255}
=============

In conclusion, ICH-IVH animals developed severe learning and memory loss, motor impairment followed by complex mitochondrial enzyme dysfunction, neurochemical disruptions, oxidative stress elevation, and increased neuroinflammatory markers. Chronic SNL therapy provides a neuroprotective effect by improving behavioral and neurochemical deficits. In addition, SNL shows a synergistic effect when used in post brain hemorrhagic conditions in rats in conjunction with standard drug therapy (DNP 3, MM 20, CLB 20, PGB 30). Therefore, SNL could be a possible therapeutic strategy associated with post-brain hemorrhagic behavioral and neurochemical changes to improve neuronal dysfunction.
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[^1]: Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus DNP3, MEM20, and CLB20 (One way ANOVA followed by Tukey's post hoc test).

[^2]: Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus DNP3, PGB30 and CLB20 (One way ANOVA followed by Tukey's post hoc test).

[^3]: Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus MEM20, DNP3 and CLB20 (One way ANOVA followed by Tukey's post hoc test).

[^4]: Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus MEM20, CLB20 and PGB30 (One way ANOVA followed by Tukey's post hoc test).

[^5]: Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus PGB30, MEM20, and DNP3 (One way ANOVA followed by Tukey's post hoc test).

[^6]: Data expressed as mean ± SEM (n = 6). \* p \< 0.05 versus sham control and SNL60 *perse*; \# p \< 0.05 versus ALB; \#@ p \< 0.05 versus ALB + SNL40; \$ p \< 0.05 versus ALB + SNL60; \$β p \< 0.05 versus DNP3, MEM20 and CLB20 (One way ANOVA followed by Tukey's post hoc test).
